Nuveen
CMPX icon

Nuveen’s Compass Therapeutics CMPX Stock Holding History

Nuveen’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
1,010,562
+719,590
+247% +$2.12M ﹤0.01% 2530
2026
Q1 		$1.54M Buy
290,972
+2,048
+0.7% +$11.8K ﹤0.01% 2376
2025
Q4 		$1.55M Buy
288,924
+29,713
+11% +$137K ﹤0.01% 2403
2025
Q3 		$907K Hold
259,211
– – ﹤0.01% 2668
2025
Q2 		$674K Sell
259,211
-45,293
-15% -$93.4K ﹤0.01% 2778
2025
Q1 		$579K Hold
304,504
– – ﹤0.01% 2855
2024
Q4 		$442K Hold
304,504
– – ﹤0.01% 3025
2024
Q3 		$560K Hold
304,504
– – ﹤0.01% 2977
2024
Q2 		$305K Hold
304,504
– – ﹤0.01% 3148
2024
Q1 		$603K Hold
304,504
– – ﹤0.01% 2913
2023
Q4 		$475K Sell
304,504
-93,030
-23% -$161K ﹤0.01% 3019
2023
Q3 		$783K Buy
397,534
+5,663
+1% +$14K ﹤0.01% 2671
2023
Q2 		$1.25M Buy
+391,871
New +$1.23M ﹤0.01% 2561

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's CMPX Position: Q2 2026 in Review

Nuveen increased its Compass Therapeutics (CMPX) stake by 247% in Q2 2026, buying an estimated $2.12M and bringing the position to 1,010,562 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Nuveen first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Nuveen held 1,010,562 shares of Compass Therapeutics worth $2.21M as of Q2 2026.
  • Nuveen bought 719,590 Compass Therapeutics shares in Q2 2026, an estimated $2.12M.
  • Compass Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2530 holding.
  • Nuveen first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.